The First Discovery of a Single Digit Nanomolar Small Molecule Blocker of a Protein-protein Interaction Target

Video   Jul 03, 2015

 



About the Speaker
Dr. Nils Hansen is the CEO and founder of Vipergen ApS. He is the principal inventor of the enabling YoctoReactor® and Binder Trap Enrichment® drug discovery technology platforms. He previously worked for Praecis Pharmaceuticals Inc., (Waltham, MA, USA) and Symphogen A/S, (Copenhagen, Denmark). Dr. Hansen earned his Ph.D. in immunology from the University of Copenhagen, Denmark in 2000 and his M.Sc. in Chemistry and Biotechnology from the University of Aarhus, Denmark in 1996.Abstract
Effective small molecule PPI blocker discovery using high fidelity DNA-encoded libraries and a low-noise homogeneous screening assay. The screen employs a unique principle of trapping small molecule binders together with the protein target in miniscule droplets.

 
 
 
 

Recommended Videos

LeNeo - Fusion Instrument

Video

LeNeo fusion instrument is an automatic and single position electrical instrument that prepares glass disks for XRF as well as solutions (borate and peroxide) for AA and ICP analysis.

WATCH NOW

Biggest Science News Stories of 2017

Video

We have seen some amazing scientific breakthroughs in 2017, here is a selection of our favourites.

WATCH NOW

Biologic Agents: Treatment of Autoimmune Diseases

Video

Dr. Andrew Gross, UCSF Rheumatology Clinic Director, explores the latest strategies in the treatment of autoimmune diseases.

WATCH NOW

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE